Stock comparison
Alnylam Pharmaceuticals
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALNY
Alnylam Pharmaceuticals
Market cap
$39.71B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Alnylam Pharmaceuticals ALNY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALNY | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 69B | MTD |
| Benjamin Graham | 80D | 65B | ALNY |
| Philip Fisher | 79B | 63C | ALNY |
| Peter Lynch | 81A | 66B | ALNY |
| Joel Greenblatt | 63C | 68B | MTD |
| Charlie Munger | 75D | 74B | ALNY |
| Terry Smith | 75B | 70B | ALNY |
Side-by-side metrics
| Metric | ALNY | MTD |
|---|---|---|
| Market cap | $39.71B | $22.29B |
| P/E (TTM) | 66.1x | 25.3x |
| EV/EBIT | 75.5x | 21.6x |
| ROIC (TTM) | 19.66% | 36.09% |
| Gross margin | 80.89% | 57.79% |
| Net margin | 13.46% | 21.4% |
| Revenue CAGR 5y | 44.82% | 2.01% |
| EPS CAGR 5y | 38.42% | 6.12% |
| Debt / Equity | 1.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALNY leads on
- Revenue CAGR 5y44.82%vs 2.01%+96%
- EPS CAGR 5y38.42%vs 6.12%+84%
- Market cap$39.71Bvs $22.29B+44%
- Gross margin80.89%vs 57.79%+29%
MTD leads on
- Debt / Equity-vs 1.2x+102%
- EV/EBIT21.6xvs 75.5x+71%
- P/E (TTM)25.3xvs 66.1x+62%
- ROIC (TTM)36.09%vs 19.66%+46%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.